Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2021

Supporting Information



Figure S1. ¹H NMR (400 MHz) spectrum of PhP(OCH₂PPh₂)₂ 1 in CDCl₃. The peak at 2.36 ppm is due to the toluene methyl group as an impurity.



Figure S2. ¹³C NMR (125.7 MHz) spectrum of PhP(OCH₂PPh₂)₂ 1 in CDCl₃.



Figure S3. ³¹P NMR (161.9 MHz) spectrum of PhP(OCH₂PPh₂)₂ 1 in CDCl₃.



Figure S4. ATR-IR spectrum of PhP(OCH₂PPh₂)₂ 1.



Figure S5. HRMS spectrum of PhP(OCH₂PPh₂)₂ 1.



Figure S6. ¹H NMR (400 MHz) spectrum of P(OCH₂PPh₂)₃ 2 in CDCl₃.



Figure S7. ¹³C NMR (125.7 MHz) spectrum of P(OCH₂PPh₂)₃ **2** in CDCl₃.



Figure S8. ³¹P NMR (161.9 MHz) spectrum of P(OCH₂PPh₂)₃ 2 in CDCl₃.



Figure S9. HRMS spectrum of P(OCH₂PPh₂)₃ 2.



Figure S10. ATR-IR spectrum of P(OCH₂PPh₂)₃ 2.



Figure S11. ¹H NMR (400 MHz) spectrum of [NiCl₂{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}] **3** in CDCl₃.



Figure S12. ¹³C NMR (100.6 MHz) spectrum of [NiCl₂{PhP(OCH₂PPh₂)₂- $\kappa^{3}P,P,P$ }] **3** in CDCl₃.



Figure S13. ³¹P NMR (161.9 MHz) spectrum of [NiCl₂{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}] **3** in CDCl₃.



Figure S14. ATR spectrum of [NiCl₂{PhP(OCH₂PPh₂)₂- $\kappa^{3}P,P,P$ }] 3.



Figure S15. HRMS spectrum of $[NiCl{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}][PF_6], 4.$



Figure S16. ¹H NMR (400 MHz) spectrum of [NiCl{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}][PF₆], 4 in CDCl₃.



Figure S17. ³¹P NMR (161.9 MHz) spectrum of [NiCl{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}][PF₆], **4** in CH₂Cl₂ with D₂O external locking.



Figure S18. ¹⁹F NMR (376.5 MHz) spectrum of [NiCl{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}][PF₆], **4** in CH₂Cl₂ with D₂O external locking.



Figure S19. ATR spectrum of $[NiCl{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}][PF_6], 4.$



Figure S20. HRMS spectrum of $[NiCl{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}][PF_6], 4.$



Figure S21. ¹H NMR (400 MHz) spectrum of [NiCl{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}(XylylNC)][PF₆] **5** in CDCl₃.



Figure S22. ¹³C NMR (125.7 MHz) spectrum of $[NiCl{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(XylylNC)][PF_6]$ 5 in CDCl₃.



 $\kappa^{3}P,P,P$ }(XylylNC)][PF₆] **5** in CDCl₃.



-71.951
-73.466

Figure S24. ¹⁹F NMR (470.6 MHz) spectrum of $[NiCl{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(XylylNC)][PF_6]$ **5** in CDCl₃.



Figure S25. ATR-IR spectrum of $[NiCl{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(XylylNC)][PF_6]$ 5.



Figure S26. HRMS spectrum of $[NiCl{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}(XylylNC)][PF_6]$ **5**.



Figure S27. ¹H NMR (400 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}('BuNC)_2][PF_6]_2$ 6 in DMSO- d_6 .



Figure S28. ¹³C NMR (125.7 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(BuNC)_2][PF_6]_2$ 6 in DMSO-d₆.



Figure S29. ³¹P NMR (202.4 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(BuNC)_2][PF_6]_2$ 6 in DMSO- d_6 .



Figure S30. ATR-IR spectrum of $[Ni \{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P\}(BuNC)_2][PF_6]_2$ 6.



Figure 31. ¹⁹F NMR (470.6 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(BuNC)_2][PF_6]_2$ 6 in CDCl₃.



Figure S32. HRMS spectrum of $[Ni{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}('BuNC)_2][PF_6]_2$ 6.



Figure S33. ¹H NMR (400 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(^iPrNC)_2][PF_6]_2$ 7 in CDCl₃.



Figure S34. ¹³C NMR (125.7 MHz) spectrum of [Ni{PhP(OCH₂PPh₂)₂- $\kappa^{3}P$,*P*,*P*}(^{*i*}PrNC)₂][PF₆]₂ 7 in CDCl₃.



Figure S35. ³¹P NMR (202.4 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(iPrNC)_2][PF_6]_2$ 7 in CDCl₃.



Figure S36. ATR-IR spectrum of $[Ni{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}(^{i}PrNC)_2][PF_6]_2$ 7.



Figure S37. HRMS spectrum of $[Ni{PhP(OCH_2PPh_2)_2-\kappa^3P,P,P}(iPrNC)_2][PF_6]_2$ 7.



Figure S38. ¹⁹F NMR (470.6 MHz) spectrum of $[Ni{PhP(OCH_2PPh_2)_2 - \kappa^3 P, P, P}(i^PrNC)_2][PF_6]_2$ 7 in CDCl₃.



Figure S39. ¹H NMR (500 MHz) spectrum of [NiCl{P(OCH₂PPh₂)₃- $\kappa^4 P, P, P, P$ }][PF₆], 8 in DMSO- d_6 .



Figure S40. ¹³C NMR (125.7 MHz) spectrum of [NiCl{P(OCH₂PPh₂)₃- $\kappa^4 P, P, P, P$ }][PF₆], 8 in DMSO- d_6 .



Figure S41. ³¹P NMR (202.4 MHz) spectrum of [NiCl{P(OCH₂PPh₂)₃- $\kappa^4 P, P, P, P$ }][PF₆], **8** in DMSO- d_6 .



Figure S42. ¹⁹F NMR (470.6 MHz) spectrum of [NiCl{P(OCH₂PPh₂)₃- $\kappa^4 P, P, P, P$ }][PF₆], **8** in DMSO- d_6 .



Figure S43. ATR-IR spectrum of $[NiCl{P(OCH_2PPh_2)_3-\kappa^4P,P,P,P}][PF_6]$, 8.



Figure S44. HRMS spectrum of $[NiCl{P(OCH_2PPh_2)_3-\kappa^4P,P,P,P}][PF_6], 8$.

X-ray Structures

Single crystal X-ray diffraction data collections for all complexes were performed using Bruker-APEX-II CCD or APEX3 D8 QUEST PHOTON-II diffractometer with graphite monochromated Mo K α radiation ($\lambda = 0.71073$ Å). The space group for every structure was obtained by XPREP program. Using the GUI WingX, the structures were solved by SHELXT¹ which successfully located most of the nonhydrogen atoms. Subsequently, leastsquares refinements were carried out on F^2 using SHELXL Version 2018/3² to locate the remaining nonhydrogen atoms. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms attached to carbon atoms were fixed in calculated positions. In the case of structure 6, one of the PF_6^- anions and the solvent of crystallization CH₂Cl₂ are disordered and they were successfully resolved using SADI, EADP and SIMU restraints. The refinement data for all the structures are summarized in Table S1. Crystallographic data were deposited with the Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK. These data can be obtained free of charge upon quoting the depository numbers CCDC 2112704-2112708 from web interface (at http://www.ccdc.cam.ac.uk).

	3	4	5	6	7	8
Empirical formula	$C_{33}H_{31}Cl_4NiO_2P_3$	C32H29ClF6NiO2P4	C41H38ClF6NNiO2P4	$C_{43}H_{49}Cl_2F_{12}N_2NiO_2P_5$	$C_{41}H_{45}Cl_2F_{12}N_2NiO_2P_5$	C ₃₉ H ₃₆ ClF ₆ NiO ₃ P ₅
Formula weight	753.00	777.59	908.76	1138.30	1110.25	915.69
Wavelength (Å)	0.71073	0.71073	0.71073	0.71073	0.71073	0.71073
Temperature (K)	296	297	296	296	100	296
Crystal system	Monoclinic	Triclinic	Monoclinic	Monoclinic	Monoclinic	Cubic
Space group	$P2_{1}/c$	<i>P</i> -1	$P2_{1}/c$	$P2_1/n$	$P2_1/n$	P2 ₁ 3
a/Å	11.2965(8)	12.0853(7)	10.4860(7)	11.235(2)	10.6099(10)	16.0943(9)
b/Å	23.8196(17)	12.7608(8)	13.2706(9)	22.991(4)	22.192(2)	16.0943(9)
c/Å	12.6524(8)	12.9324(7)	29.888(2)	20.206(4)	20.122(2)	16.0943(9)
a/degree	90	106.472(3)	90	90	90	90
β /degree	98.894(3)	94.713(3)	91.166(3)	97.139(6)	91.369(3)	90
γ/degree	90	115.252(2)	90	90	90	90
Vol (Å ³)	3363.5(4)	1681.68(17)	4158.2(5)	5178.8(16)	4736.5(8)	4168.8(7)
Ζ	4	2	4	4	4	4
D_{calcd} , g cm ⁻³	1.487	1.536	1.452	1.460	1.557	1.459
μ/mm^{-1}	1.067	0.910	0.748	0.712	0.777	0.784
F(000)	1544	792	1864	2328	2264	1872
θ range (degree)	2.362 to 30.518	2.944 to 28.315	2.350 to 27.199	2.216 to 24.997	1.835 to 26.413	2.192 to 27.146
Limiting Indices	$\label{eq:16} \begin{array}{l} -16 \leq h \leq 16, \\ -32 \leq k \leq 34, \\ -18 \leq l \leq 18 \end{array}$	$\label{eq:heat} \begin{array}{l} -16 \leq h \leq 15, \\ -14 \leq k \leq 17, \\ -17 \leq l \leq 17 \end{array}$	$\begin{array}{l} -13 \leq h \leq 13, \\ -17 \leq k \leq 16, \\ -38 \leq l \leq 38 \end{array}$	$\begin{array}{l} -13 \leq h \leq 13, \\ -27 \leq k \leq 27, \\ -24 \leq l \leq 24 \end{array}$	$\begin{array}{l} -13 \leq h \leq 13, \\ -24 \leq k \leq 27, \\ -24 \leq l \leq 25 \end{array}$	-20<=h<=20 -20<=k<=20 -20<=l<=20
Total/ unique no. of reflns	57694 / 10198	23584 / 8250	81157 / 9234	105309 / 9088	59211 / 9639	62912 / 3107
$R_{ m int}$	0.0961	0.0400	0.0845	0.0911	0.0649	0.0979
Data/ restr./params.	10198/0/388	8250/0/415	9234/0/507	9088/197/546	9639/0/590	3107 / 0 / 166
GOF (F^2)	1.041	1.044	1.068	1.074	1.030	1.059
R1, wR2	0.0598, 0.0967	0.0380, 0.0947	0.0540, 0.1319	0.0658, 0.1895	0.0382, 0.0928	0.0630, 0.1675
<i>R</i> indices (all data) <i>R1</i> , <i>wR2</i>	0.1490, 0.1270	0.0610, 0.1034	0.1139, 0.1781	0.0943, 0.2038	0.0498, 0.0995	0.0924, 0.1973
Largest different peak and hole (e Å ⁻³)	0.581, -0.552	0.622, -0.558	1.243, -0.466	1.079, -0.641	0.706, -0.415	0.746 and -0.594

Table S1. Crystallographic data for complexes 3-7.



Figure S45. ¹H NMR (500 MHz) spectrum of *N*-benzyl-4-methoxyaniline in CDCl₃.



Figure S46. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-benzyl-4-methoxyaniline in CDCl₃.



Figure S47. ¹H NMR (500 MHz) spectrum of *N*-benzylaniline in CDCl₃.



Figure S48. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-benzylaniline in CDCl₃.



Figure S49. ¹H NMR (500 MHz) spectrum of *N*-benzyl-4-bromoaniline in CDCl₃.



Figure S50. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-benzyl-4-bromoaniline in CDCl₃.



Figure S51. ¹H NMR (500 MHz) spectrum of *N*-benzyl-2,6-diisopropylaniline in CDCl₃.



Figure S52. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-benzyl-2,6-diisopropylaniline in CDCl₃.



Figure S54. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-benzylpyridin-2-amine in CDCl₃.



Figure S55. ¹H NMR (500 MHz) spectrum of *N*-butyl-4-methoxyaniline in CDCl₃.



Figure S56. ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-butyl-4-methoxyaniline in CDCl₃.



Figure S57: ¹H NMR (400 MHz) spectrum of 4-methoxy-*N*-(4-methoxybenzyl)aniline in CDCl₃.



Figure S58: ¹³C{¹H} NMR (125.7 MHz) spectrum of 4-methoxy-*N*-(4-methoxybenzyl)aniline in CDCl₃.



Figure S59: ¹H NMR (400 MHz) spectrum of *N*-(4-methoxybenzyl)aniline in CDCl₃.



Figure S60: ¹³C{¹H} NMR (125.7 MHz) spectrum of *N*-(4-methoxybenzyl)aniline in CDCl₃.



Figure S61: ¹H NMR (400 MHz) spectrum of *N*-(4-methoxybenzyl)pyridin-2-amine in CDCl₃.



Figure S62: ${}^{13}C{}^{1}H$ NMR (125.7 MHz) spectrum of *N*-(4-methoxybenzyl)pyridin-2-amine in CDCl₃.



Figure S63: ¹H NMR (500 MHz) spectrum of *N*-benzylidene-4-methoxyaniline in CDCl₃.

References

2. G. M. Sheldrick, Acta Cryst. Sect. C: Struct. Chem., 2015, 71, 3.

^{1.} G. M. Sheldrick, Acta Cryst. Sect. A: Found. Crystallogr., 2015, 71, 3.